CTIS2024-514837-39-00进行中（未招募）1 期
PILOT STUDY OF THE EFFECT OF A SUBSTANCE P ANTAGONIST,APREPITANT, ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITHOBSTRUCTIVE SLEEP APNEA AND ARTERIAL HYPERTENSION SYNDROME - (APHOS3) - 2020/0431/HP
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Subject with severe obstructive sleep apnea syndrome defined by an apnea and hypopnea index (AHI) = 30/h in polysomnography or ventilatory polygraphy (requiring continuous positive pressure equipment), Subject with essential hypertension treated medically or by lifestyle and dietary measures or newly diagnosed (defined by SBP = 140 and/or PAD = 90 mmHg according to current SFHTA-HAS recommendations), Patient's agreement to replace diuretics with another neutral antihypertensive treatment (which does not interfere with the reninangiotensin system) before taking the experimental treatment and throughout the study (if applicable), Regulatory Criteria: o Adult aged 18 to 75 / o Affiliation to a social security scheme / o Person who has read and understood the information letter and signed the consent form / o For women: - of childbearing age, need for effective mechanical contraception (condoms) during the study and within 2 months of the last month taken, with a negative urine pregnancy test on inclusion and for the duration of the study study at V2 and V4, - postmenopausal: amenorrhea not medically induced for at least 12 months before the V1 visit
排除标准
- •Minor subject or subject over 75 years old, Criteria relating to associated pathologies leading to particular risks: o Subject with excessive daytime sleepiness with a contraindication to driving (Epworth score > 16) / o Severe uncontrolled cardiovascular disease: myocardial infarction or stroke in the last 6 months, unstable angina, heart failure. / o Knowledge of chronic renal failure defined by a glomerular filtration rate < 60 mL/min/1.73m2 for more than 3 months) or moderate hepatic failure defined by ALT and/or AST transaminases > 3N) / o Epilepsy o Known acute infections related to HIV, HBV or HCV / o Active cancer undergoing treatment or immunosuppressive treatments, Criteria for aprepitant: o Hypersensitivity to the active substance (aprepitant) or/and one of the excipients (contents and capsule shell) o People with hereditary problems of fructose intolerance, glucosegalactose malabsorption syndrome, or sucrase/isomaltase deficiency o Subject treated with drugs metabolized by cytochromes CYP3A4 and CYP2C9: corticosteroids (dexamethason, methylprednisolone), anti vitamin K (warfarin, acenocoumarol), benzodiazepines (midazolam, alprazolam, triazolam), anti-depressants (nefazodone), quinidine, hormonal contraceptives , ergot alkaloids (ergotamine, diergotamine), immunosuppressants (ciclosporin, tacrolimus, sirolimus, everolimus), morphine (alfentanil, fentanyl), antibiotics (rifampicin and clarithromycin-type macrolides, telithromycin), azole antifungals (ketoconazole, itraconazole, voriconazole, posaconazole), anti-virals (protease inhibitors), anti-epileptics (phenytoin, carbamazepine, phenobarbital), chemotherapies (etoposide, vinorelbine, ifosfamide, irinotecan), diuretics (tolbutamide) and herbal preparations containing St. John's wort. As well as these molecules in co-administration pimozide, terfenadine, astemizole and cisapride., Placebo contraindication criteria: Lactose intolerance
研究者
相似试验
进行中（未招募）
1 期
Pilot study of the effect of a substance P antagonist, aprepitant, on aldosterone and cortisol secretions in healthy volunteersThe aim is to measure plasma aldosterone and cortisol concentrations in basal conditions and in response to different stimulation tests of the adrenal functionEUCTR2008-003367-40-FRCHU de Rouen20
已完成
不适用
A study on the effects of application of compounded stenone cream (fermented product enriched with plant stenones) on subcutaneous fat and visceral fat.Healthy adultsJPRN-UMIN000039249imeQ RD inc.30
招募中
不适用
An observational study examining bioactive substances and genetic polymorphism for personalized pharmacotherapy in hyperlipidemiaHyperlipidemiaJPRN-UMIN000006018Osaka City University Graduate School of Medicine300
已完成
不适用
A pharmacokinetics study of the major ingredient and its metabolites after single ingestion of test foodot applicableJPRN-UMIN000031452Zenyaku Kogyo Co., Ltd.5
已完成
不适用
A pharmacokinetics study of the major ingredient and its metabolites after multiple ingestions of test foodot applicableJPRN-UMIN000034637Zenyaku Kogyo Co., Ltd.5